What is William Blair's Forecast for CNTX Q2 Earnings?

Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities researchers at William Blair issued their Q2 2026 earnings estimates for shares of Context Therapeutics in a research report issued to clients and investors on Tuesday, April 29th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of ($0.09) for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Context Therapeutics' current full-year earnings is ($0.51) per share. William Blair also issued estimates for Context Therapeutics' Q4 2026 earnings at ($0.07) EPS.

Several other analysts have also recently commented on CNTX. D. Boral Capital reiterated a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and set a $5.00 target price on shares of Context Therapeutics in a research note on Friday, March 21st. JMP Securities assumed coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price target on the stock. Finally, Citizens Jmp raised Context Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 8th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $6.17.

Context Therapeutics Stock Up 0.8 %

CNTX traded up $0.01 during midday trading on Thursday, hitting $0.87. 30,000 shares of the company were exchanged, compared to its average volume of 300,208. The firm has a market capitalization of $78.01 million, a P/E ratio of -0.96 and a beta of 2.18. The firm's 50 day moving average price is $0.78 and its 200-day moving average price is $1.16. Context Therapeutics has a 1-year low of $0.55 and a 1-year high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, topping analysts' consensus estimates of ($0.05) by $0.01.

Institutional Trading of Context Therapeutics

Large investors have recently made changes to their positions in the company. MPM Bioimpact LLC bought a new position in Context Therapeutics in the fourth quarter worth approximately $15,441,000. Franklin Resources Inc. lifted its holdings in shares of Context Therapeutics by 115.9% in the 4th quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company's stock worth $4,204,000 after purchasing an additional 2,149,392 shares in the last quarter. Allostery Investments LP acquired a new stake in Context Therapeutics in the 4th quarter valued at $998,000. Blue Owl Capital Holdings LP increased its stake in Context Therapeutics by 17.5% during the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company's stock valued at $6,676,000 after purchasing an additional 946,638 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Context Therapeutics by 412.8% during the fourth quarter. Renaissance Technologies LLC now owns 338,435 shares of the company's stock worth $355,000 after buying an additional 272,435 shares during the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.